147 related articles for article (PubMed ID: 2862652)
21. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.
Yasui N; Kondo T; Suzuki A; Otani K; Mihara K; Furukori H; Kaneko S; Inoue Y
Int Clin Psychopharmacol; 1999 Mar; 14(2):113-8. PubMed ID: 10220126
[TBL] [Abstract][Full Text] [Related]
22. Haloperidol response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of determination of plasma haloperidol levels.
Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
[TBL] [Abstract][Full Text] [Related]
24. Haloperidol blood levels in acute mania with psychosis.
Chou JC; Czobor P; Dacpano G; Richardson N; Tuma I; Trujillo M; Cooper TB; Volavka J
J Clin Psychopharmacol; 2001 Aug; 21(4):445-7. PubMed ID: 11476130
[TBL] [Abstract][Full Text] [Related]
25. Blood levels of haloperidol and clinical outcome in schizophrenia.
Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
[TBL] [Abstract][Full Text] [Related]
26. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
Yao JK; van Kammen DP
Schizophr Res; 1994 Feb; 11(3):209-16. PubMed ID: 8193060
[TBL] [Abstract][Full Text] [Related]
27. Serum haloperidol concentration and clinical response in schizophrenia.
Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
[TBL] [Abstract][Full Text] [Related]
28. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
30. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
Volavka J; Cooper TB; Czobor P; Meisner M
Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103
[TBL] [Abstract][Full Text] [Related]
31. Serum haloperidol concentrations and clinical response in acute psychosis.
Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol.
Pelton GH; Devanand DP; Bell K; Marder K; Marston K; Liu X; Cooper TB
Am J Geriatr Psychiatry; 2003; 11(2):186-93. PubMed ID: 12611748
[TBL] [Abstract][Full Text] [Related]
33. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
Libiger J; Czobor P; Volavka J
Psychiatry Res; 1994 May; 52(2):107-14. PubMed ID: 7972567
[TBL] [Abstract][Full Text] [Related]
34. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
Van Putten T; Marder SR; Mintz J; Poland RE
Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
[TBL] [Abstract][Full Text] [Related]
35. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Cesková E; Svestka J
Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
[TBL] [Abstract][Full Text] [Related]
36. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
Chou JC; Douyon R; Czobor P; Volavka J; Cooper TB
Psychiatry Res; 1998 Oct; 81(1):51-5. PubMed ID: 9829650
[TBL] [Abstract][Full Text] [Related]
37. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
[TBL] [Abstract][Full Text] [Related]
38. Further evidence of a dose-response threshold for haloperidol in psychosis.
Stone CK; Garve DL; Griffith J; Hirschowitz J; Bennett J
Am J Psychiatry; 1995 Aug; 152(8):1210-2. PubMed ID: 7625474
[TBL] [Abstract][Full Text] [Related]
39. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
40. Haloperidol plasma and red blood cell levels and clinical antipsychotic response.
Garver DL; Hirschowitz J; Glicksteen GA; Kanter DR; Mavroidis ML
J Clin Psychopharmacol; 1984 Jun; 4(3):133-7. PubMed ID: 6736272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
